179 related articles for article (PubMed ID: 20890226)
1. SOX10 expression in superficial spreading and nodular malignant melanomas.
Agnarsdóttir M; Sooman L; Bolander A; Strömberg S; Rexhepaj E; Bergqvist M; Ponten F; Gallagher W; Lennartsson J; Ekman S; Uhlen M; Hedstrand H
Melanoma Res; 2010 Dec; 20(6):468-78. PubMed ID: 20890226
[TBL] [Abstract][Full Text] [Related]
2. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
3. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.
Maelandsmo GM; Holm R; Nesland JM; Fodstad Ø; Flørenes VA
Clin Cancer Res; 2003 Aug; 9(9):3383-8. PubMed ID: 12960126
[TBL] [Abstract][Full Text] [Related]
4. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma.
Bakos RM; Maier T; Besch R; Mestel DS; Ruzicka T; Sturm RA; Berking C
Exp Dermatol; 2010 Aug; 19(8):e89-94. PubMed ID: 19845757
[TBL] [Abstract][Full Text] [Related]
5. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
6. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma.
Flørenes VA; Faye RS; Maelandsmo GM; Nesland JM; Holm R
Clin Cancer Res; 2000 Sep; 6(9):3614-20. PubMed ID: 10999753
[TBL] [Abstract][Full Text] [Related]
7. HER3 expression in cutaneous tumors.
Wimmer E; Kraehn-Senftleben G; Issing WJ
Anticancer Res; 2008; 28(2A):973-9. PubMed ID: 18507044
[TBL] [Abstract][Full Text] [Related]
8. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas.
Fagiani E; Giardina G; Luzi L; Cesaroni M; Quarto M; Capra M; Germano G; Bono M; Capillo M; Pelicci P; Lanfrancone L
Cancer Res; 2007 Apr; 67(7):3064-73. PubMed ID: 17409413
[TBL] [Abstract][Full Text] [Related]
9. Sox10: a pan-schwannian and melanocytic marker.
Nonaka D; Chiriboga L; Rubin BP
Am J Surg Pathol; 2008 Sep; 32(9):1291-8. PubMed ID: 18636017
[TBL] [Abstract][Full Text] [Related]
10. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
11. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
12. Analysis of APAF-1 expression in human cutaneous melanoma progression.
Baldi A; Santini D; Russo P; Catricalà C; Amantea A; Picardo M; Tatangelo F; Botti G; Dragonetti E; Murace R; Tonini G; Natali PG; Baldi F; Paggi MG
Exp Dermatol; 2004 Feb; 13(2):93-7. PubMed ID: 15009102
[TBL] [Abstract][Full Text] [Related]
13. A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas.
Tacha D; Qi W; Ra S; Bremer R; Yu C; Chu J; Hoang L; Robbins B
Arch Pathol Lab Med; 2015 Apr; 139(4):530-6. PubMed ID: 25436903
[TBL] [Abstract][Full Text] [Related]
14. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar.
Ramos-Herberth FI; Karamchandani J; Kim J; Dadras SS
J Cutan Pathol; 2010 Sep; 37(9):944-52. PubMed ID: 20653825
[TBL] [Abstract][Full Text] [Related]
15. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
16. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein D expression in cutaneous malignant melanoma.
Miranda E; Vizoso F; Martín A; Quintela I; Corte MD; Seguí ME; Ordiz I; Merino AM
J Surg Oncol; 2003 Jun; 83(2):99-105. PubMed ID: 12772203
[TBL] [Abstract][Full Text] [Related]
18. The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas.
Bolander A; Agnarsdóttir M; Strömberg S; Ponten F; Hesselius P; Uhlen M; Bergqvist M
Cancer Genomics Proteomics; 2008; 5(6):293-300. PubMed ID: 19287070
[TBL] [Abstract][Full Text] [Related]
19. SOX10 expression in malignant melanoma, carcinoma, and normal tissues.
Mohamed A; Gonzalez RS; Lawson D; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):506-10. PubMed ID: 23197006
[TBL] [Abstract][Full Text] [Related]
20. HER3 is a determinant for poor prognosis in melanoma.
Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]